This trial is evaluating whether motexafin gadolinium will improve 1 primary outcome and 2 secondary outcomes in patients with Prostate Cancer. Measurement will happen over the course of 2 to 14 Days.
This trial requires 30 total participants across 2 different treatment groups
This trial involves 2 different treatments. Motexafin Gadolinium is the primary treatment being studied. Participants will all receive the same treatment. There is no placebo group. The treatments being tested are not being studied for commercial purposes.
The data indicated that between 2 in 10 and 2 in 20 men undergo a PSA test each year and that 1 in 10 men will be diagnosed with prostate cancer.
Prostate cancer is uncommon among Caucasians, but it occurs commonly among Americans of African descent. In this group, risk is positively correlated with socioeconomic status. This has implications for the design of prostate cancer screening studies.
Given the significant effects of metastatic disease, the treatment of localized prostate cancer using the usual therapeutic approaches must be encouraged. The ability to define an effective and effective treatment is lacking for metastatic prostate cancer. A combination of androgen ablation and chemotherapy may prevent progression to androgen independent disease. We discuss the likelihood of cures for patients at various clinical stages with metastatic disease.
Prostate cancer is commonly treated through a variety of therapeutic modalities. For localized and locally advanced cases, radiation therapy and surgery are the treatment of choice. Prostate-specific antigen testing is used to determine the prognosis of a case and if further treatment is indicated. When surgery is required then radical prostatectomy is the standard of care, while radiation treatments may be used in patients with localized disease.
Symptoms of prostate cancer are present in the general population. If signs of prostate cancer are present the first step is to conduct a digital rectal examination (DRE) with digital examination of the penis and/or scrotum, especially if there is history of symptoms.
Prostate tumor has been classified as malignant or non-malignant in accordance with its growth rate, malignancy, metastatic potential and other pathological factors, or as benign or premalignant in accordance with its benign growth rate, and asymptomatic in accordance with low serum PSA level. Prostate cancer is the second leading cause of death in men. It is estimated to cause 7,590 deaths in the United States in 2014.\n
In this research paper, the new research regarding prostate cancer is reviewed. Specifically, the research papers related to prostate cancer have not change their findings since the discovery of the PSA test. The PSA testing as a screening test for prostate cancer was developed and introduced in the 1980s. The PSA test is the most commonly used blood test for prostate cancer and has been helpful in detecting prostate cancer, however, its use has also introduced problematic consequences to millions of men. The PSA test may not be as accurate as it was before as the number of PSA tests performed increased. In recent years, the PSA test has also been introduced in the digital rectal examinations as an aid in the detection of prostate cancer lesions.
The indication of motexafin gadolinium treatment is limited to a group of patients with recurrent or progressive metastatic disease after prior chemotherapy and radiotherapy. The treatment with motexafin gadolinium is an option in patients with nonmetastases and locally advanced prostate cancer when the PSA is < 70 ng/ml.
The novel imaging agent, motexafin gadolinium, provides a noninvasive alternative to MRI for the assessment of metastatic disease in patients with known or suspected prostate cancer. The low incidence of adverse events may make it a useful adjunct to MRI in the preoperative staging of prostate cancer.
The current results suggest that the mechanism underlying the efficacy of motexafin gadolinium on prostate cancers may be an enhancement of cell death through a mitochondria-mediated apoptosis, and a possible inhibition of angiogenesis.